EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence

Wei Wei, Zhi-Nan Chen, Ke Wang

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241512317 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Wei Wei und 2 weiteren Autor:innen. Beteiligte Einrichtung: National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an 710032, China. Hauptthemen laut MEDLINE: Receptors, Chimeric Antigen, Neoplasms. Die Arbeit wurde bisher 73-mal zitiert (Crossref) und nennt 145 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Young Talent fund of the University Association for Science and Technology in Shaanxi, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As an emerging treatment strategy for malignant tumors, chimeric antigen receptor T (CAR-T) cell therapy has been widely used in clinical practice, and its efficacy has been markedly improved in the past decade. However, the clinical effect of CAR-T therapy is not so satisfying, especially in solid tumors. Even in hematologic malignancies, a proportion of patients eventually relapse after receiving CAR-T cell infusions, owing to the poor expansion and persistence of CAR-T cells. Recently, CRISPR/Cas9 technology has provided an effective approach to promoting the proliferation and persistence of CAR-T cells in the body. This technology has been utilized in CAR-T cells to generate a memory phenotype, reduce exhaustion, and screen new targets to improve the anti-tumor potential. In this review, we aim to describe the major causes limiting the persistence of CAR-T cells in patients and discuss the application of CRISPR/Cas9 in promoting CAR-T cell persistence and its anti-tumor function. Finally, we investigate clinical trials for CRISPR/Cas9-engineered CAR-T cells for the treatment of cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, Chimeric AntigenNeoplasmsHumansT-LymphocytesCRISPR-Cas SystemsGene EditingNeoplasm Recurrence, LocalImmunotherapy, Adoptive

Stichwörter der Autor:innen

CAR-T cellCRISPR/Cas9exhaustionmemory phenotypepersistence

Substanzen

Receptors, Chimeric Antigen

Autor:innen und Institutionen

  • National Translational Science Center for Molecular Medicine & Department of Cell Biology, Fourth Military Medical University, Xi'an 710032, China.

Förderung

  • the Young Talent fund of the University Association for Science and Technology in Shaanxi, China

Zitieren

APA

Wei, W., Chen, Z. N., & Wang, K. (2023). CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241512317

Vancouver

Wei W, Chen ZN, Wang K. CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241512317

BibTeX
@article{Wei2023,
  author = {Wei, Wei and Chen, Zhi-Nan and Wang, Ke},
  title = {CRISPR/Cas9: A Powerful Strategy to Improve CAR-T Cell Persistence},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241512317}
}
Kostenlos starten →